Tirzepatide

• Week 1-2: Start 2.5 mg; fullness and some nausea are common
• Week 2-4: Stomach upset often eases; early weight change varies
• Week 4-8: 5 mg at week 5; on the pill? Use backup birth control
• Week 9-13: Step up to 7.5 mg, then 9 mg at week 13
• Side effects: Mostly stomach upset; get help for severe belly pain or allergy signs

More on each stage

Week 1-2

You start at 2.5 mg (12.5 units), a starter dose that lets your stomach adjust; the label says it is not approved as a long-term dose. Tirzepatide slows your stomach most after the very first dose, so early fullness and some nausea are common. Community users often report appetite dropping fast in the first couple of weeks.

Week 2-4

Blood levels build with each weekly shot and level off after about 4 doses. Most stomach side effects in the trials happened while doses were going up, then eased over time. Weight changes this early are usually small and vary a lot from person to person.

Week 4-8

At week 5 you step up to 5 mg (25 units). Nausea or other stomach symptoms may come back for a while after the step-up, then settle. If you take birth-control pills, use backup protection for 4 weeks after this and every later increase.

Week 9-13

At week 9 you step up to 7.5 mg (37.5 units), and at week 13 to the store dose of 9 mg (45 units). In a study of 1,545 people from the big weight-loss trial who took at least 3 of every 4 doses, 82% had lost 5% or more of their weight by week 12. Of those who had not, 90% got there by week 72, but they lost less overall: 11.0% of their weight on average at week 72, versus 22.5% for the faster group.

Side effects

Most often nausea, diarrhea, constipation, burping, or heartburn, mainly after dose increases. Stop and get medical help for severe belly pain that won't go away, signs of an allergic reaction, or vomiting you can't keep fluids down.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• Large, lasting weight loss

  FDA-labeled

  In a 72-week trial of 2,539 adults with obesity, average weight change was -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg weekly, versus -3.1% on a dummy shot. Everyone also followed a diet and exercise plan.13

• Most of the weight lost is fat

  Clinical trial

  In a body-scan (DXA) study of 160 people inside that trial, about 75% of the weight people lost was fat and about 25% was lean tissue such as muscle. Fat mass fell 33.9%; lean mass fell 10.9%.4

• Lower blood sugar in type 2 diabetes

  FDA-labeled

  In a 40-week trial of 1,879 adults with type 2 diabetes, A1C (average blood sugar) fell 2.01 to 2.30 points on 5-15 mg, versus 1.86 points on semaglutide 1 mg. People also lost more weight on tirzepatide.62

• Less sleep apnea

  FDA-labeled

  In two 52-week trials of adults with obesity and moderate-to-severe sleep apnea, breathing pauses fell by about 25-29 events an hour on 10 or 15 mg, versus about 5 on a dummy shot.1

• Fewer heart-failure events

  Clinical trial

  In a trial of 731 adults with obesity and heart failure with preserved ejection fraction (a stiff heart that still pumps normally), 9.9% on tirzepatide versus 15.3% on a dummy shot died of cardiovascular causes (heart or blood-vessel disease) or had a worsening heart-failure event, over a median follow-up of 104 weeks (about 2 years). Worsening heart-failure events alone: 8.0% versus 14.2%.7

• Quieter food noise

  Community report

  Users often describe fewer cravings and less constant thinking about food, with appetite dropping in the first couple of weeks. These are self-reports; strength of the effect varies a lot.15

What it has been studied for

• Weight loss and keeping weight off in adults with obesity, or overweight with a weight-related condition (as Zepbound)13FDA-labeled
• Moderate-to-severe obstructive sleep apnea in adults with obesity (as Zepbound)1FDA-labeled
• Blood-sugar control in type 2 diabetes (as Mounjaro)26FDA-labeled
• Heart failure with preserved ejection fraction in people with obesity7Clinical trial
• Fatty-liver disease with inflammation and scarring (MASH), phase 28Clinical trial

Tirzepatide is a lab-made peptide built on a gut hormone called GIP. It works like a key that fits two locks your body normally uses to sense food, the ones for GIP and for GLP-1. A fatty tail makes it stick to a protein in your blood (albumin), so one shot lasts about a week. Together, these signals tell the brain you are full and slow down the stomach. They also help the pancreas release insulin only when blood sugar is high. People eat less, and most of the weight they lose is fat.

Peak

About 1 day after the shot (middle value 24 hours; range 8 to 72 hours). About 80% of the dose reaches the blood, and belly, thigh, and upper arm give similar levels.

Half-life

About 5 days (the label gives 5-6 days in people with overweight or obesity). That is why one shot a week works. Levels build up and level off after 4 weekly doses.

Cleared

The FDA label does not say how long it takes to leave the body. It gives a half-life of about 5-6 days, which means the amount in your blood drops by half every 5-6 days after the last shot. The body breaks tirzepatide down into pieces; no intact drug shows up in urine or stool.

Half-life is how long it takes the body to remove half of a dose.1

Once a week. Any time of day, with or without food. Pick one day of the week and keep it. Every week on the same day. Missed a dose? Take it within 4 days (96 hours); after that, skip it and take the next one on your usual day. Keep any two doses at least 3 days (72 hours) apart. Units are for a 60 mg vial mixed with 3 mL water (20 mg per mL).

Step-up plan

When	Dose	Units
Weeks 1-4 (starter dose) Start here	2.5 mg	12.5 units
Weeks 5-8	5 mg	25 units
Weeks 9-12	7.5 mg	37.5 units
Week 13 on (store dose)	9 mg	45 units

• Lower end · FDA-labeled start

  2.5 mg once weekly, stepping up about every 4 weeks

  The FDA-labeled starting titration the community follows almost universally; compounded users mirror it from multi-dose vials.1

• Most common · where most settle

  7.5-10 mg once weekly

  Where most community members actually settle for maintenance — enough appetite suppression with fewer GI side effects than the maximum dose.1315

• Higher end · highest labeled dose

  15 mg once weekly

  The highest FDA-labeled maintenance dose, reached after gradual 2.5 mg step-ups. Community results usually sit below the trial ceiling at this dose.1

• Community practice (about 400 user reports)

  Most follow the label's 4-week steps. Many settle at 7.5-10 mg a week instead of going to 15 mg. Some stay 6-8 weeks at the 2.5 and 5 mg steps to ease side effects. A smaller group splits the weekly dose into 2 shots 3-4 days apart. Split dosing and longer low-dose stretches have not been tested in controlled trials.1315

Research protocols

• FDA label (Zepbound)

  Start at 2.5 mg once a week for 4 weeks, then 5 mg. Step up by 2.5 mg after at least 4 weeks on each dose. Long-term doses for weight are 5, 10, or 15 mg a week; for sleep apnea 10 or 15 mg. The maximum is 15 mg a week. If a dose is not tolerated, a lower long-term dose can be used.1

• Weight-loss trial (SURMOUNT-1, 2,539 adults, 72 weeks)

  Fixed weekly doses of 5, 10, or 15 mg, reached by 2.5 mg steps every 4 weeks (full dose by week 4, 12, or 20), plus a diet and exercise plan.35

• Stop-or-continue trial (88 weeks, in the FDA label)

  783 people started tirzepatide, stepping up over up to 20 weeks to the highest dose they tolerated (10 or 15 mg a week). The 670 who reached week 36 (93% on 15 mg, 7% on 10 mg) had lost 20.9% on average. Half of them then switched to a dummy shot and gained back 14.0% from their week-36 weight by week 88; the half who stayed on lost another 5.5%.1

• Heart-failure trial (SUMMIT, 731 adults)

  Up to 15 mg once a week, or a dummy shot, for at least 52 weeks (people were followed for a median of 104 weeks).7

Tirzepatide carries a boxed warning for thyroid C-cell tumors (rodent data) and risks including pancreatitis and gallbladder disease. Compounded tirzepatide is not FDA-approved; the FDA confirmed no shortage exists and has restricted compounding.

Dosing guidance built from the cited research and community reports. It is not a prescription.

On

Ongoing, with no planned end

Break

No routine break

Why the break helps

Unlike most peptides, tirzepatide is not cycled. It is a long-term medicine, and a break does not help. In an 88-week trial, people who switched to a dummy shot after 36 weeks on tirzepatide regained 14% of their body weight over the next year, while people who stayed on lost another 5.5%. The store protocol is also continuous. If you want to stop or lower your dose, plan it with a doctor.

Common

• Nausea (25-29% of people on 5-15 mg in trials, versus 8% on a dummy shot)

  What to do Eat smaller meals, stop when you feel full, and go lighter on greasy or fried food. It is usually worst after a dose increase and then fades. If it does not settle, stay on your current dose longer instead of stepping up, or go back to the last dose you tolerated.

• Diarrhea (19-23%) or vomiting (8-13%)

  What to do Drink plenty of fluids to avoid dehydration, which can harm your kidneys. Call a doctor if it does not go away.

• Constipation (11-17%)

  What to do Drink more water and add fiber. It is usually mild, and diet changes or over-the-counter remedies usually help. Get help if you cannot pass stool and your belly is swollen or painful.

• Indigestion, heartburn, or burping, including 'sulfur burps' (about 4-10% each)

  What to do Eat smaller meals. Community users avoid sulfur-rich foods such as eggs and broccoli-family vegetables when burps smell like eggs.

• Redness, itching, or bruising where you inject (6-8%)

  What to do Move to a new spot every week and never inject into irritated skin. Get help right away for swelling of the face or throat.

• Tiredness (5-7%) or dizziness (4-5%)

  What to do Eat regularly, drink fluids, and stand up slowly. Low blood pressure was more common in people also on blood-pressure medicine, so tell your doctor if you take one.

• Hair shedding (4-5%; 7.1% of women versus 0.5% of men)

  What to do It is linked to weight loss, and no one in the trials stopped tirzepatide because of it. Community users say it often starts around month 3 and grows back over 6-12 months.

Stop and get help

• Pancreatitis: severe belly pain that will not go away, sometimes spreading to the back, with or without vomiting

  What to do Stop tirzepatide and get medical help right away.

• Gallbladder problems: pain in the upper belly, fever, yellow skin or eyes, or clay-colored stools

  What to do Call a doctor right away. Gallbladder inflammation was more common on tirzepatide (0.7%) than on a dummy shot (0.2%).

• Serious allergic reaction: swelling of the face, lips, tongue, or throat; trouble breathing or swallowing; severe rash; fainting; very fast heartbeat

  What to do Stop tirzepatide and get emergency help.

• Dehydration and kidney strain from vomiting or diarrhea that will not stop

  What to do Get medical care, especially if you cannot keep fluids down or are making very little urine.

• Severe stomach or bowel problems, including blockage: severe constipation, swelling, or being unable to pass stool or gas

  What to do Get medical care promptly.

• Low blood sugar, mainly if you also use insulin or a sulfonylurea: shakiness, sweating, confusion, fast heartbeat

  What to do Eat or drink fast sugar (juice, glucose tablets) and call your doctor. Your diabetes medicine dose may need to come down.

• Possible thyroid tumor signs: a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that will not go away

  What to do See a doctor. Tirzepatide caused thyroid tumors in rats; whether it does in people is unknown.

• Vision changes if you have type 2 diabetes: a fast drop in blood sugar can briefly worsen diabetic eye disease (retinopathy)

  What to do Tell your doctor about any change in your vision. If you have had diabetic retinopathy, have your eyes checked while on tirzepatide. It has not been studied in people with advanced retinopathy or diabetic macular edema (swelling in the back of the eye).

• Surgery or sedation while on tirzepatide: a slow stomach can let food enter the lungs

  What to do Tell every doctor before any surgery or procedure that uses anesthesia or deep sedation.

Do not use if

• You or a family member have had medullary thyroid cancer, or you have MEN 2 (a hereditary gland-tumor condition)
• You have had a serious allergic reaction to tirzepatide
• You are pregnant or trying to get pregnant; the label says to stop when pregnancy is recognized
• You have severe gastroparesis (a stomach that empties very slowly)
• You already use semaglutide, retatrutide, or any other GLP-1 or tirzepatide product
• You are under 18 and using it for weight loss; safety in children has not been established (Mounjaro is approved for type 2 diabetes from age 10, by prescription)

Sources14

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F) until you inject, and never leave it in a hot car. Do not use it if it turns cloudy or has specks in it.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.3 mL (30-unit) U-100 insulin syringe with half-unit marks, so small doses are easy to read. Doses above 30 units (up to 75 here) need a 0.5 mL (50-unit) syringe, or a 1 mL (100-unit) one above 50 units.

1. Start low. The 9 mg store dose is your target dose, reached at week 13. You start at 2.5 mg a week for 4 weeks, then step up every 4 weeks, as the FDA label does. 9 mg sits in the 7.5-10 mg range where community users most often settle.
2. With this mix, every 1 unit line on a U-100 insulin syringe holds 0.2 mg. Draw 12.5 units for 2.5 mg, 25 units for 5 mg, 37.5 units for 7.5 mg, 45 units for the 9 mg store dose, or 50 units for 10 mg.
3. Drawing the dose: wipe the top with an alcohol swab, pull the plunger back to fill the syringe with air equal to your dose, push that air into the vial, then turn the vial upside down. Keep the needle tip in the liquid and draw a little past your line. Tap the syringe so bubbles rise, then push the plunger back to the exact line.
4. Look before you inject. The FDA label says tirzepatide should be clear and colorless to slightly yellow. Do not use it if it is cloudy, has particles, or has changed color.
5. Push the plunger all the way, then keep the needle in your skin for at least 5 seconds so the whole dose goes in. If you see blood, press with gauze; do not rub.
6. Women taking birth-control pills: tirzepatide can make the pill work less well. Use a non-pill method, or add condoms, for 4 weeks after you start and for 4 weeks after each dose increase.
7. Use a new sterile syringe every time, never share one, and drop used needles in a sharps container.

• Tesamorelin

  Some community users pair it with tirzepatide hoping to protect lean mass while losing weight (a niche stack). That is a real concern: about a quarter of the weight lost on tirzepatide was lean tissue. Tesamorelin cut deep belly (visceral) fat by 15% over 26 weeks in an HIV trial. Tesamorelin can raise blood sugar, so check your blood sugar if you combine them.1341011

• BPC-157

  Some community users add BPC-157 by mouth to ease tirzepatide's stomach side effects (a niche stack). BPC-157 protected the gut lining in rats. It has not been tested for this in people or alongside tirzepatide, and the store sells BPC-157 as an injection, not by mouth.1312

Interactions

• Semaglutide, retatrutide, or any other GLP-1 or tirzepatide product (including others from this store)

  The FDA label says not to combine tirzepatide with any other tirzepatide or GLP-1 product. Semaglutide and retatrutide also act on the GLP-1 receptor.

  What to do Use only one of these at a time.

• Insulin or sulfonylureas (such as glipizide or glyburide)

  Low blood sugar. In one trial, 10.3% of people on tirzepatide plus a sulfonylurea had low blood sugar, versus 2.1% on tirzepatide without one.

  What to do Talk to your doctor before starting; your diabetes medicine dose may need to come down. Check your blood sugar.

• Birth-control pills

  Slower stomach emptying lowers how much of the pill gets into your blood, so it may not prevent pregnancy as well.

  What to do Switch to a non-pill method, or add condoms, for 4 weeks after starting and for 4 weeks after each dose increase.

• Pills that must stay at an exact level, such as warfarin

  A slower stomach can change how fast pills are absorbed.

  What to do Tell the doctor who manages that medicine so they can monitor you, especially in the first weeks and after dose increases.

• Blood-pressure medicines

  Among people on tirzepatide, low blood pressure happened to 2.2% of those also taking blood-pressure medicine versus 1.2% of those who were not. Dehydration makes it more likely.

  What to do Drink fluids, stand up slowly, and ask your doctor whether your blood-pressure dose needs adjusting as you lose weight.

• Anesthesia or deep sedation (surgery, endoscopy)

  Food can stay in a slowed stomach and be breathed into the lungs.

  What to do Tell the team doing your procedure that you take tirzepatide, well before the day.

Videos

• What is MOUNJARO? How it works and how this Diabetes Drug Became a Weight Loss Game-Changer!The Stealth Doctor · 2025
• Ozempic & Tirzepatide Side Effects Explained (Doctor Reacts to the GLP-1 Data)Dr. Spencer Nadolsky · 2025
• GLP-1 weight-loss drugs: What the science says | 90 Seconds w/ Lisa KimStanford Medicine · 2026

Sources

1. 1FDA Zepbound (tirzepatide) prescribing information, revised 02/2026Drug label
2. 2FDA Mounjaro (tirzepatide) prescribing information, DailyMedDrug label
3. 3Jastreboff et al., NEJM 2022 (SURMOUNT-1 weight-loss trial)Clinical trial
4. 4Look et al., Diabetes Obes Metab 2025 (SURMOUNT-1 body-composition DXA study)Study
5. 5Ard et al., Diabetes Obes Metab 2025 (SURMOUNT-1 early vs late responders)Study
6. 6Frías et al., NEJM 2021 (SURPASS-2, tirzepatide vs semaglutide in type 2 diabetes)Clinical trial
7. 7Packer et al., NEJM 2025 (SUMMIT heart-failure trial)Clinical trial
8. 8Loomba et al., NEJM 2024 (SYNERGY-NASH fatty-liver trial)Clinical trial
9. 9Samms et al., J Clin Invest 2021 (GIP action in fat tissue, obese mice)Study
10. 10Falutz et al., NEJM 2007 (tesamorelin belly-fat trial in HIV)Clinical trial
11. 11FDA Egrifta WR (tesamorelin) prescribing information, 03/2025Drug label
12. 12Sikiric et al., Curr Pharm Des 2011 (BPC-157 gastrointestinal review)Review
13. 13Peptide Protocol Wiki: Tirzepatide community protocols (400 reports)Community
14. 14Peptide Protocol Wiki: Tirzepatide side effectsCommunity
15. 15GLP3 Planner: Tirzepatide Reddit roundup (r/tirzepatidecompound, r/Zepbound)Community

Where people discuss it

• r/tirzepatidecompound (subreddit, 176K+)
• Peptide Protocol Wiki — Tirzepatide community
• GLP3 Planner — Tirzepatide Reddit roundup

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented